InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $1.535 0.31 (25.31%)+
Announcement
Release
4 May 2026 9:14AM
Price at Release
$1.225
Full Release
download
Summary
PYC Therapeutics Limited, an Australian biotechnology company, announced the presentation of clinical trial data for their investigational drugs VP-001 and PYC-001 at the ARVO conference in Denver. VP-001 targets Retinitis Pigmentosa type 11 (RP11) by addressing PRPF31 gene haploinsufficiency, showing clinically meaningful improvements in visual acuity and quality of life for patients. PYC-001 aims to treat Autosomal Dominant Optic Atrophy (ADOA) by increasing OPA1 protein levels to restore mitochondrial function. Both drugs have shown promising safety and efficacy profiles in early trials, offering potential first-in-class treatments for these genetic eye diseases.
Key Points
  • PYC Therapeutics announced trial data at ARVO conference.
  • VP-001 targets Retinitis Pigmentosa type 11 (RP11).
  • PYC-001 targets Autosomal Dominant Optic Atrophy (ADOA).
  • VP-001 addresses PRPF31 gene haploinsufficiency.
  • PYC-001 increases OPA1 protein levels.
  • Both drugs show promising safety and efficacy.
  • Potential first-in-class treatments for eye diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.